Research Progress of Dai and Western Medicine in the Treatment of Gouty Arthritis

This paper reviews the pathogenesis,diagnostic criteria,and treatment means of gouty arthritis from the perspectives of Western medicine and Dai medicine in order to provide a reference for clinical medication.

Research Progress in the Treatment of Gouty Nephropathy with Dai and Western Medicine

If gouty nephropathy is not treated properly,repeated attacks can gradually lead to nephrotic syndrome.This may bring pain to patients and affect their quality of life.The main goal of Western medicine in the treatment of gouty nephropathy is to stop acute attacks,control serum uric acid and avoid recurrence.Yet there are many adverse reactions to long-term use.Dai medicine has unique efficiency in improving clinical symptoms and controlling relapses.Meanwhile it can avoid the potential risks associated with too low control of blood uric acid.Therefore,this paper reviewed the research status of Dai and Western medicine in the treatment of gouty nephropathy in order to provide reference for clinical medication.

Ethnomedicine: fading or flowering? ——Heritage and development of Dai Medicine

Ethnomedicine is an important component of ethnic culture, and a part of traditional medicine in China. We undertook great considerations and in-depth investigations of Dai Medicine, as well as analyses of its basic concepts, current situations, and interrelations with Traditional Chinese Medicine. The issues regarding Dai Medicine's heritage and development are also discussed.

Advances in Studies on Treatment of Hepatic Fibrosis with Dai and Western Medicine

Hepatic fibrosis is a necessary stage in the development of chronic liver disease to cirrhosis.Western medicine drug treatment takes etiological treatment,symptomatic treatment and anti-fibrosis treatment as the main means and aims to protect the liver and improve hepatic function while there are many adverse reactions after long-term administration.However,Dai medicine mainly focuses on balancing the four towers and five aggregates,and regulating the"three plates".Hence it has slight side effects and is safe and effective.Therefore,this paper reviewed the current status of Dai and Western medicine in the treatment of hepatic fibrosis,in order to provide reference for clinical medication.

Annual advances of Chinese minority traditional medicine in 2020

Chinese minority traditional medicine is a traditional medicine formed during the long-term medical practice of various ethnic groups and is the crystallization of the wisdom of the people in all ethnic groups in China.The unique meaning carried by Chinese minority traditional medicine makes it an inseparable and important part of traditional Chinese medicine.The rich clinical experience and theoretical studies with different Chinese minority traditional medicine provide new ideas and new methods for Chinese medicine development.The pieces of literature published in 2020 on the traditional application analyzed the phytochemical composition,pharmacological effects,and mechanisms of the different ethnic groups including Tibetan,Mongolian,Zhuang,Dai,and Uyghur medicines,among others.This study found that some projects were stalled or delayed due to the coronavirus disease 2019 outbreak in 2020 compared with 2019,resulting in a decrease in the number of articles in certain fields.However,studied on Chinese minority traditional medicine have shown an overall upward trend this year with the Tibetan,Mongolian,and Dai medicines as the top three.In addition,the Chinese minority traditional medicine application under the coronavirus disease 2019 epidemic situation background was also summarized.Consequently,this study found that among the Chinese minority traditional medicine-related publications in 2020,publications using Chinese minority traditional medicine to treat coronavirus disease 2019 account for a certain percentage.Thus,this article systematically reviews and summarizes the related research of Chinese minority traditional medicine published in 2020 and provides references for future Chinese minority traditional medicine development.

Survey of traditional Dai medicine reveals species confusion and potential safety concerns: a case study on Radix Clerodendri Japonicum

The adulteration of herbal products is a threat to consumer safety. In the present study, we surveyed the species composition of commercial Radix Clerodendri Japonicum products using DNA barcoding as a supervisory method. A reference database for plant-material DNA-barcode was successfully constructed with 48 voucher samples from 12 Clerodendrum species. The database was used to identify 27 Radix Clerodendri Japonicum decoction piece samples purchased from drug stores and hospitals. The DNA sequencing results revealed that only 1 decoction piece(3.70%) was authentic C. japonicum, as recorded in the Dai Pharmacopeia, whereas the other samples were all adulterants, indicating a potential safety issue. The results indicate that decoction pieces that are available in the market have complex origins and that DNA barcoding is a suitable tool for regulation of Dai medicines.

STILBENOIDS AND PHENANTHRENES FORM ARUNDINA GRAMINIFOLIA(DAI MONORITY MEDICINE) AND ANTITUMOR BIOACTIVITY

The objective was to isolate,elucidate and analyze the bioactive chemicals from the tuber of Arundina graminifolia(Dai Monority Medicine).The compounds were extracted by 95%alcohol and isolated by column chromatography on silica gel,Sephedax LH-20 and ODS.The structures were determined by UV,IR,NMR and MS spectra.

Acute toxicity study of Aspidopterys obcordata aqueous extract in Sprague-Dawley rats

OBJECTIVE: To examine the acute toxicity of an aqueous extract of Aspidopterys obcordata(A. obcordata) in Sprague Dawley rats.METHODS: The rats were orally administered a dose of 5000 mg/kg body weight and observed continuously for 6 h and then daily for 14 days. Control rats were administered distilled water. The effect of the extract on general behavior, body weight, and food and water intake were measured.After 14 days, the rats were sacrificed and their organs(liver, heart, spleen, lungs, kidney, adrenal glands, ovaries, and testes) were removed for macroscopic examination. The body and organ weights in addition to hematology(e.g., hemoglobin and white blood cell counts) and clinical blood biochemistry(e.g., albumin and bilirubin) were also examined.RESULTS: There were no deaths recorded, and the rats treated with A. obcordata showed no signs of toxicity. All measured parameters in rats treated with A. obcordata were unaffected when compared with those in control rats. The acute toxicity(LD_(50))was estimated to be > 5000 mg/kg body weight.CONCLUSION: Our results demonstrate the safety of an acute oral administration of an aqueous extract of A. obcordata in rats and indicate that future subacute and long-term toxicity testing of A. obcordata is warranted.